Helix builds North America's largest linked clinico-genomic dataset
New CapabilitiesPrecision health company crosses 500,000 records and launches its first AI discovery tool
June 2nd, 2026: Helix hits 500,000 records and launches AI toolsNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Helix said its GenoSphere platform now holds more than 500,000 linked clinico-genomic records. That makes it the largest such dataset in North America. The San Mateo company also released the first of a planned set of artificial intelligence tools built to mine that data for drug targets.
A linked record pairs one patient's full genetic sequence with their long-term electronic health record. At half a million records, researchers can spot rare variants tied to disease and watch how patients with specific genotypes respond to treatment. That scale is what pharmaceutical companies pay for.
Why it matters
Drug discovery moves faster when companies can match genetic variants to real patient outcomes, and this dataset gives pharma a half-million Americans to study.
Questions about this story
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
Sequences patients through health-system partners and sells de-identified, EHR-linked genetic data to pharmaceutical companies.
Runs the Tapestry study with Helix, one of the largest clinical exome sequencing programs in the United States.
Timeline
July 2015 June 2026
-
Helix hits 500,000 records and launches AI tools
Latest MilestoneGenoSphere crosses 500,000 linked records, the largest such dataset in North America. Helix releases the first of a planned suite of AI discovery tools.
-
Helix crosses 100,000 linked records
MilestoneThe GenoSphere dataset passes 100,000 linked clinico-genomic records, an early scale benchmark.
-
Mayo Clinic Tapestry study begins
PartnershipMayo Clinic and Helix announce Tapestry, a plan to sequence the exomes of 100,000 Mayo patients.
-
Helix pivots from consumer to clinical
StrategyHelix winds down its consumer DNA marketplace and refocuses on clinical sequencing through health-system partners.
-
Helix launches as Illumina spinoff
FoundingIllumina spins out Helix with more than $100 million in initial funding to build a consumer DNA platform.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
UK Biobank reaches 500,000 participants (2010)
The UK Biobank, funded by Wellcome Trust, the Medical Research Council, and the NHS, enrolled 500,000 British adults between 2006 and 2010. Each gave blood and urine samples, agreed to genotyping, and consented to long-term linkage with their NHS health records.
Researchers gained access to a population-scale resource linking genotype to clinical outcomes, billed at modest fees for academic use.
UK Biobank has powered thousands of published studies and is the data source behind major pharma deals, including Regeneron's 2014 exome-sequencing partnership.
Helix is building the equivalent for North America. The 500,000 threshold matters because UK Biobank set it as the scale needed for statistical power on rare variants.
Amgen acquires deCODE genetics (2012)
Amgen paid $415 million for Iceland-based deCODE, which held genetic and health data on a large share of Iceland's population. The acquisition was driven by deCODE's ability to validate drug targets using its linked dataset.
The deal set a market price for population-scale linked genetic databases.
Amgen used deCODE data to support development of evolocumab, a PCSK9 inhibitor that became a multi-billion-dollar cardiovascular drug.
This is the playbook Helix is selling: a linked dataset that lets a pharma buyer skip years of target validation. The deCODE precedent gives pharma a known return on investment.
GSK pays $300 million for 23andMe data access (2018)
GlaxoSmithKline paid 23andMe $300 million for a four-year exclusive partnership to use the company's database of consenting customer genotypes for drug discovery.
The deal validated consumer genetic data as a pharma research input and lifted 23andMe's pre-IPO valuation.
GSK reportedly identified roughly 50 drug targets using the data, but 23andMe later struggled financially as consumer DNA demand softened.
This shows both the upside Helix is chasing and the risk: pharma will pay for linked genetic data, but the dataset operator still needs a sustainable underlying business to keep growing it.
